Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 13, 2020

LabVantage Awarded US Army Contract for LIMS COVID-19 Vaccine Support

The company will supply its LIMS to the Walter Reed Army Institute of Research (WRAIR) to support vaccine production programs for COVID-19 at WRAIR’s pilot bioproduction facility.

LabVantage Solutions, a provider of laboratory informatics solutions and services, announced on Oct. 13, 2020 that the US Army Medical Research Acquisition Activity has presented it with a contract to supply its LabVantage Pharma laboratory information management system (LIMS) to the Walter Reed Army Institute of Research (WRAIR) to support vaccine production programs for COVID-19 at WRAIR’s pilot bioproduction facility.

According to a LabVantage press release, the company’s LIMS package for pharmaceutical and biotech laboratories comes with batch management, stability testing, consumables management, environmental monitoring, barcode label printing, instrument calibration, certification, and maintenance.

“We developed LabVantage Pharma to make it fast and easy for pharmaceutical and biotech organizations to acquire and implement a state-of-the-art laboratory information management system to enable efficient and compliant quality manufacturing,” said John Heiser, CEO of LabVantage, in the press release. “We appreciate that WRAIR understood the unique benefits of LabVantage Pharma and moved to expedite its acquisition via a sole source contract. We are very proud that our purpose-built LIMS is now helping the WRAIR address the urgent need for new vaccines and therapies to combat COVID-19 and other serious diseases.”

Source: LabVantage​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.